Phase II, 51 (46 GBM, 3 AA, other 2); Phase III, 296 recurrent GBM
Infusion MTIC was 0.5 μg/mL; up to 6 d well tolerated; median survival 42.7 weeks (95% CI, 35.6–55.6) for GBM in Phase II and 36.4 weeks in Phase III, comparable to Gliadel Wafer
Headache, dysphasia, seizure, weakness, and pulmonary embolism